Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model

Cancer Immunology, Immunotherapy

Volumn 65, Issue 5, 2016, Pages 613-624

  Xia, Qiu ^a   Zhang, Fang Fang ^a   Geng, Fei ^a   Liu, Chen Lu ^a   Xu, Ping ^a   Lu, Zhen Zhen ^a   Yu, Bin ^a   Wu, Hui ^a   Wu, Jia Xin ^a   Zhang, Hai Hong ^a   Kong, Wei ^a   Yu, Xiang Hui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

CAF; DNA vaccine; FAP ; Immune suppression; Immunotherapy

Indexed keywords

CANCER VACCINE; COLLAGEN TYPE 1; DNA VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; SEPRASE; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; FEMALE; FIBROBLAST; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME; VACCINATION;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COLLAGEN TYPE I; FEMALE; FIBROBLASTS; GELATINASES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, INBRED BALB C; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR MICROENVIRONMENT; VACCINATION; VACCINES, DNA;

EID: 84961635226     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1827-4     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
2. Prud’homme GJ (2005) DNA vaccination against tumors. J Gene Med 7:3–17
3. Nguyen T, Urban J, Kalinski P (2014) Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 3:135–150
4. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen Y-T (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22–32
5. Acharya PS, Zukas A, Chandan V, Katzenstein A-LA, Puré E (2006) Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 37:352–360
6. Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87:7235–7239
7. Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A (1997) Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 71:383–389
8. Goldstein LA, Ghersi G, Piñeiro-Sánchez ML, Salamone M, Yeh Y, Flessate D, Chen W-T (1997) Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta 1361:11–19
9. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ (1993) Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 53:3327–3335
10. Micke P (2004) Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45:S163–S175
11. Östman A, Augsten M (2009) Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Curr Opin Genet Dev 19:67–73
12. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E (2005) Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 65:11156–11163
13. Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767–4772
14. Wen Y, Wang CT, Ma TT et al (2010) Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 101:2325–2332
15. Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E (2005) Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res 11:5566–5571
16. Fearon DT (2014) The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res 2:187–193
17. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401
18. Ribatti D, Vacca A (2008) The role of microenvironment in tumor angiogenesis. Genes Nutr 3:29–34
19. Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80
20. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273
21. O’Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393–398
22. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103
23. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275–290
24. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330:827–830
25. LeBleu VS (2015) Imaging the tumor microenvironment. Cancer J 21:174–178
26. Liu R, Li H, Liu L, Yu J, Ren X (2012) Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 13:123–129
27. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee H-O, Wang H, Lai JH, Bachovchin WW, Weiner LM (2005) Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 4:351–360
28. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos A-K, Quest AF, Kiessling R (2010) Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 59:81–92
29. Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI (2007) Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 30:169–179
30. Wang Y-Q, Zhang H-H, Liu C-L et al (2013) Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol 17:9–17
31. Wang Y, Liu C, Xia Q et al (2014) Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep 31:1437–1444
32. Zhang H, Wang Y, Liu C et al (2012) DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 61:1857–1867
33. You Q, Jiang C, Wu Y et al (2012) Subcutaneous administration of modified vaccinia virus ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol 75:77–84
34. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116:1955–1962. doi:10.1172/JCI26532
35. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4:e7965
36. Henry LR, Lee H-O, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen W-T, Cheng JD (2007) Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13:1736–1741
37. Hofheinz R-D, Al-Batran S-E, Hartmann F et al (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48
38. Scott AM, Wiseman G, Welt S et al (2003) A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647
39. Niedermeyer J, Kriz M, Hilberg F et al (2000) Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 20:1089–1094
40. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505–36512